For example, identification of the Bcr–Abl fusion in chronic myeloid leukemia (CML) led to the development of imatinib, the first targeted cancer therapeutic, and marked the beginning of the targeted therapy era [7,8]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.